To investigate the association between GLP-1 receptor agonist (RA) use and all-cause mortality and recurrence-free survival (RFS) in breast cancer patients, highlighting the potential implications for treatment strategies.
Key Findings:
GLP-1 RA use was associated with decreased all-cause mortality in breast cancer patients, with a notable percentage reduction.
Patients using GLP-1 RAs showed improved recurrence-free survival compared to non-users, with specific survival rates provided.
The study highlights potential benefits of GLP-1 RAs beyond diabetes management in breast cancer outcomes.
Interpretation:
The findings suggest that GLP-1 RAs may offer protective effects against mortality and recurrence in breast cancer patients, warranting further investigation into their role in clinical practice.
Limitations:
Retrospective design may introduce biases.
Data was limited to EHRs, which may not capture all relevant clinical factors.
Generalizability may be limited to the specific populations studied.
Potential confounding factors were not fully accounted for.
Conclusion:
GLP-1 receptor agonists may improve survival and recurrence outcomes in breast cancer patients, indicating a need for further research in this area, particularly in diverse populations and varying treatment contexts.
by Kristina L. Tatum, Bassam Dahman, Aniyah Stevenson, Sarah E. Williford, J. Brian Cassel, Hua Zhao, Jie Shen, Kandace P. McGuire, Obinna Diala, Racheal Oladimeji, W. Greg Hundley, Bernard F. Fuemmeler
